Faculty Information - 設楽　久美

（Last updated : 2020-08-17 21:16:49）

設楽　久美
Department Other, Other Department of Internal Medicine, Division of Rheumatology

Position

■ Published papers

1.	Original article	The minimally important difference for the Japanese version of the health assessment questionnaire in patients with rheumatoid arthritis in daily practice. 2017/05
2.	Original article	Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. 2017/04
3.	Original article	Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis. 2017/02
4.	Original article	The minimally important difference for the Japanese version of the health assessment questionnaire in patients with rheumatoid arthritis in daily practice. 2016/10
5.	Original article	Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. 2016/07
6.	Original article	Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; Analysis of the IORRA database. 2016
7.	Original article	Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. 2015/03
8.	Original article	Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis 2015/03
9.	Original article	Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab. 2013/11
10.	Original article	Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study. 2013/11
11.	Review article	The influence of individual joint impairment on functional disability in rheumatoid arthritis using a large observational database of Japanese patients. 2012
12.	Original article	Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. 2010/11
13.	Original article	Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. 2010/11
14.	Original article	Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort,IORRA. 2010/06
15.	Original article	Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. 2010/03
16.	Original article	Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis. 2010/01
17.	Original article	Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis. 2010
18.	Original article	Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. 2010
19.	Original article	Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort,IORRA. 2010
20.	Original article	Mortality of and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA 2010
21.	Original article	Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006 2010
Display 5 items
Display all(21)

■ Academic conference presentation

1.	Methotrexate dose reduction during DAS28 remission was a signficant factor associated with early deterioration in patients with rheumatoid arthritis from the IORRA cohort. 2015/06
2.	The minimally important difference in the European quality of life-five dimensions(EQ-5D) in patients with rheumatoid arthritis based on the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort. 2014/11/16
3.	Treatment for Rheumatoid arthritis patients after a lymphoproliferative disorder. 2014/06/13
4.	Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort 2013/10
5.	Clinical factors associated with the progression of functional impairment in rheumatoid arthritis patients who maintained the remission criteria defined by the new ACR/EULAR criteria. 2013/06
6.	Suppression of disease activity with methotrexate and/or TNF inhibitors but not corticosteroid ameliorates the functional disability of RA patients in a large prospective cohort study. 2010/06/19
7.	Genetic Contribution to the Clinical Features of Rheumatoid Arthritis 2010/06
8.	Analysis of RA patients without biologics despite the sustaining high disease activity in a Japanese prospective observational cohort 2009/06
9.	Euro QOL (EQ-5D) based QOL in 5,023 Japanese patients with rheumatoid arthritis in an observational cohort IORRA 2009/06
10.	Incidence of malignancies in Japanese patients with rheumatoid arthritis ?Analysis of IORRA cohort 2009/06
11.	Iucidence of malignancies in Japanese patients with rheumatoid arthritis-analysis of IORRA cohort 2009/06
12.	Which joint improvement contributed in the better functional disability in patients with RA 2009/06
Display 5 items
Display all(12)